# A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

> **NCT02150499** · PHASE3 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** levalbuterol tartrate HFA inhalation aerosol
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02150499
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02150499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02150499, "A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02150499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*